Loading
The development and validation of an 18-gene urine test that outperformed the blood PSA test at finding prostate cancers worth treating.
In a validation cohort of 743, the area under the curve was 0.81 for MPS2 and 0.82 for MPS2+, against 0.60 for PSA alone and 0.77 for the Prostate Health Index, with negative predictive values of 95 to 99 per cent for grade group 2 or higher cancer.
A urine RNA panel can rule out significant prostate cancer for many men.
Shares PSA and MRI-first prostate cancer screening, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker, Prostate cancer.
Shares MyProstateScore 2.0, PSA and MRI-first prostate cancer screening, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Prostate cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker, Prostate cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker, Prostate cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares MyProstateScore 2.0, PSA and MRI-first prostate cancer screening, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Prostate cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/